Tirzepatide

Tirzepatide is a synthetic 39-amino-acid peptide studied as a dual receptor agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is one of the most extensively studied incretin-based compounds in the published literature, with a large controlled-trial record in defined patient populations. Sold in our catalog as GLP-TZ 30mg. For laboratory research use only.

Available Options

Research Context

Tirzepatide (development code LY3298176) is a 39-amino-acid synthetic peptide based on a GIP sequence scaffold, incorporating aminoisobutyric acid substitutions and a C20 fatty-diacid side chain linked through a lysine residue, a modification that extends its circulating half-life. It acts as an agonist at both the GIP and GLP-1 receptors, a dual profile that distinguishes it pharmacologically from selective GLP-1 receptor agonists.

The mechanistic literature includes controlled preclinical work: in obese mouse models, GIP receptor agonism by tirzepatide was shown to mediate insulin-sensitizing effects independent of body weight change (Samms and colleagues, 2021, J Clin Invest) — animal data that helped establish the pharmacological rationale for the dual-agonist design. The human evidence base is substantial for a compound of this class: the phase 3 SURPASS-2 trial (Frias and colleagues, 2021, N Engl J Med) enrolled adults with type 2 diabetes and measured HbA1c and body weight against an active comparator over 40 weeks, and the phase 3 SURMOUNT-1 trial (Jastreboff and colleagues, 2022, N Engl J Med) enrolled adults with obesity and measured body weight change over 72 weeks. These are controlled trials in defined clinical populations, conducted under regulatory oversight; they characterize the compound as studied in those populations and are not evidence of effect elsewhere.

Open questions in the research landscape include how the GIP receptor component contributes to the compound's observed pharmacology relative to GLP-1 receptor agonism alone, the cardiovascular and longer-duration outcomes data still emerging from ongoing trials, and structure-activity questions around receptor potency balance that continue to inform next-generation multi-agonist design. In laboratory settings, tirzepatide is widely used as a reference dual agonist for incretin receptor signaling studies.

This material is supplied as a lyophilized powder with purity verified by HPLC and a published certificate of analysis. It is intended strictly for laboratory research use and is not for human or veterinary use.

Specifications

Storage & Handling

Store the lyophilized powder at -20C, protected from light and moisture. After reconstitution, refrigerate at 2-8C and use the solution promptly.

For handling guidance, see our peptide reconstitution and storage guide, and use the reconstitution calculator to plan solution volumes for laboratory work.

Certificate of Analysis

Related Compounds

• Retatrutide
• Tesamorelin
• MOTS-C

References

1. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. J Clin Invest. 2021. PMID 34003802
2. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021. PMID 34170647
3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022. PMID 35658024